Učitavanje...
Mechanisms of resistance to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors (‘targeted therapies’) largely...
Spremljeno u:
| Izdano u: | Br J Cancer |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765236/ https://ncbi.nlm.nih.gov/pubmed/29319049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.434 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|